Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALI I AMJAD

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1568690287
CMS profile
70704
Location
NEW CASTLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$356.58

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $345.08 3
Education $11.50 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $213.86 2
AstraZeneca Pharmaceuticals LP $131.22 1
PFIZER INC. $11.50 1

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALI I AMJAD

NPI 1568690287 · CMS profile ID 70704

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW CASTLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568690287?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALI I AMJAD, NPI 1568690287, CMS profile ID 70704. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568690287?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ALI I AMJAD, NPI 1568690287, CMS profile ID 70704. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568690287?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ALI I AMJAD, NPI 1568690287, CMS profile ID 70704, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1568690287?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $356.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $131.2211/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685761585 CMS
E.R. Squibb & Sons, L.L.C. $116.5210/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651339853 CMS
PFIZER INC. $11.5009/05/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673277147 CMS
E.R. Squibb & Sons, L.L.C. $97.3406/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651339851 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $356.58 4
PY2020 $133.83 1
PY2021 $291.05 6
PY2022 $81.08 3
PY2023 $92.16 4
PY2024 $309.62 9
PY2025 $50.30 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,447.15 27
PY2024 Principal investigator $153,570.17 81
PY2023 Principal investigator $135,809.64 30
PY2022 Principal investigator $125,424.34 16
PY2021 Principal investigator $145,880.33 7
PY2020 Principal investigator $158,325.59 8
PY2019 Principal investigator $65,494.13 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,457.99 12/31/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer No dispute reported 06/30/2026 991126969
Principal investigator 1 AstraZeneca Pharmaceuticals LP $261.38 12/31/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON No dispute reported 06/30/2026 991135149
Principal investigator 1 BeiGene, Ltd. $1,000.00 12/29/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043037101
Principal investigator 1 BeiGene, Ltd. $1,872.00 12/29/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043093355
Principal investigator 1 BeiGene, Ltd. $2,451.00 12/22/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043038583
Principal investigator 1 BeiGene, Ltd. $1,083.00 12/22/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043111227
Principal investigator 1 BeiGene, Ltd. $1,083.00 11/17/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043043003
Principal investigator 1 BeiGene, Ltd. $1,083.00 11/17/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043115751
Principal investigator 1 BeiGene, Ltd. $2,638.00 11/17/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043116005
Principal investigator 1 BeiGene, Ltd. $2,991.00 10/23/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043069918
Principal investigator 1 BeiGene, Ltd. $1,083.00 10/23/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043093635
Principal investigator 1 BeiGene, Ltd. $2,720.00 10/23/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043097515
Principal investigator 1 BeiGene, Ltd. $1,083.00 10/23/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043111569
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 10/19/2023 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1006217469
Principal investigator 1 BeiGene, Ltd. $4,099.00 09/25/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043061041
Principal investigator 1 BeiGene, Ltd. $2,250.00 09/13/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043091019
Principal investigator 1 GlaxoSmithKline, LLC. $800.00 09/12/2023 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1006217481
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 07/28/2023 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1006217463
Principal investigator 1 BeiGene, Ltd. $2,250.00 06/30/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043025843
Principal investigator 1 BeiGene, Ltd. $500.00 06/30/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043088679
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,175.00 05/09/2023 Non-covered Recipient Entity
Allegheny Health Network
Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) No dispute reported 06/30/2026 1027468831
Principal investigator 1 GlaxoSmithKline, LLC. $3,463.50 04/11/2023 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1006217475
Principal investigator 1 BeiGene, Ltd. $450.00 03/03/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043022945
Principal investigator 1 BeiGene, Ltd. $4,000.00 03/03/2023 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Car No dispute reported 06/30/2026 1043023619
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,600.00 02/15/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON No dispute reported 06/30/2026 991130607
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,852.15 02/10/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Phase IB, Open-Label, Randomized, Multi-Center Platform Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 991133469
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,167.04 02/08/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) No dispute reported 06/30/2026 991132483
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,355.34 01/18/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer No dispute reported 06/30/2026 991124159
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,623.24 01/18/2023 Non-covered Recipient Entity
ALLEGHENY-SINGER RESEARCH INSTITUTE
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 991131709
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,468.00 01/06/2023 Non-covered Recipient Entity
Allegheny Health Network
Phase III Study Adj GEJ & Esoph (US EU) (mono) - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal or Gastroesophageal Junction Cancer No dispute reported 06/30/2026 1027468845